New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)

Patent No. EP3700529 (titled "New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)") was filed by Boehringer Ingelheim on Oct 12, 2018. The application was issued on Jul 9, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOTTI & FERRARIApr 9, 2026BOTTI & FERRARI
TEVA PHARMACEUTICALSApr 2, 2026ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3700529

BOEHRINGER INGELHEIM
Application Number
EP18785961A
Filing Date
Oct 12, 2018
Status
Granted And Under Opposition
Jun 6, 2025
Publication Date
Jul 9, 2025